Journal article
Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants
Safety and immunogenicity of Sabin-IPV (sIPV) was evaluated in a double-blind, randomized, controlled, dose-escalation trial in the target population. Healthy infants (n=20/group) aged 56-63 days, received a primary series of three intramuscular injections with low-, middle- or high-dose sIPV with or without aluminum hydroxide or with the conventional IPV based on wild poliovirus strains (wIPV). Virus-neutralizing titers against both Sabin and wild poliovirus strains were determined before and 28 days after three vaccinations.
Authors
Languages
- English
Publication year
2014
Journal
Vaccine
Volume
9
Type
Categories
Diseases
Tags
